Enhance your translational Alzheimer’s disease research with comprehensive analysis of 770 standardized genes designed to reliably assay AD phenotypes and disease progression for mouse model development and human tissue screening. Content covers 30 clinically derived AD-associated modules discovered in the AMP-AD consortium study of human brain tissue.
Apply for 24 samples worth of the nCounter® AD Panel by Oct. 31!
Why is this grant program right for you?
- You are currently developing AD mouse models or are using models to screen novel therapeutics or monitor disease progression.
- You are trying to discover promising new therapeutic targets or biomarkers for neurodegenerative disease using mouse models or FFPE human brain tissue.
- You are passionate about being a part of the movement to advance Alzheimer’s disease research.
- The winner brings the project and samples, NanoString provides the gene expression panels.
- Winners can run 24 samples using the nCounter Mouse or Human AD Panel through an nCounter® Analysis System provided by their organization or through a service provider.
Eight winners will be announced on November 11th, 2019, by e-mail.
nCounter® AD Panel:
- Monitor disease progression with age
- Assay novel therapeutics
- Characterize AD
|Number of Targets||
770 including internal reference genes
|Standard Input Material (No amplification required)||25 ng-300 ng|
|Samples Type(s)||FFPE-derived RNA, total RNA, fragmented RNA, PBMCs, whole blood/plasma, iPS cells|
|Species||Mouse and Human|
|Time to Results||Approximately 24 hours|
|Data Analysis||nSolver™ Analysis Software, Advanced Analysis Modules|
Grant Proposal Guidelines:
- Proposals must involve high-plex gene expression of neurodegenerative disease, preferably Alzheimer’s disease specifically. Learn more about NanoString technology by clicking on the links below:
- Include abstract title and authors
- Include abstract which describes project goals and outline of how NanoString’s nCounter AD Panel would help accelerate your research (maximum of 500 words)
- Include statement on the availability of samples for use in your project (for example, please state whether the samples are in your possession/accessible from collaborators/biobanks/repositories)
- Grant submission must be received on or before October 31st at 11:59pm PST
- Potential impact on Alzheimer’s disease research
- Sample availability
- Well-defined and publishable end points
- Ability for project completion in less than two months after winner receives panels
Sharing of Grant Submissions and Publication of Results:
All grant submissions are confidential to the individual submitter and will not be published or distributed, provided that submissions may be shared on a confidential basis with The Jackson Laboratory in order to receive input on the selection of grant winners. Upon project completion, each grant winner agrees to participate in one of the following activities relating to the specific project, with specific details of the applicable activity to be mutually agreed upon in good faith by NanoString and each winner: webinar, case study, blog post, or poster presentation. Each winner agrees that NanoString shall have the right to use anonymized data from the winner's project in application notes or marketing literature.
Applicants must be actively enrolled or employed at an academic research institution in a capacity in which they perform life science research and have the ability to analyze samples within two months of award notification. Winner(s) of the grant will receive 24 reactions worth of the NanoString Human or Mouse AD Panel for use in this program.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.